Biologics Coordinators Drive Biosimilar Brand Selection in Rheumatology

Biologics coordinators in rheumatology clinics are exercising substantial control over the selection of biosimilar medications, according to data from a survey conducted by Spherix Global Insights.

The survey findings indicate that 80% of biologics coordinators report having significant influence over which biosimilar brands are chosen for patient use.

This trend highlights a shift in the operational dynamics of modern rheumatology practices. While physicians retain the ultimate authority to prescribe a specific therapy, the coordinators are the staff members responsible for navigating the complexities of medication selection, and implementation.

The Evolving Role of the Biologics Coordinator

The influence exerted by these coordinators suggests that the administrative and navigational aspects of biologic therapy have become central to the treatment process. The role often involves managing the logistics between the prescribing physician, the patient, and the pharmaceutical providers.

Ryan Rex, the senior director of insights at Spherix Global Insights, emphasized the growing importance of these positions within the clinical setting.

The fact that biologic coordinators report having significant influence over biosimilar brand selection highlights how central these roles have become in modern rheumatology practices.

Ryan Rex, senior director of insights at Spherix Global Insights

As the use of biosimilars continues to integrate into rheumatology, the ability of coordinators to manage brand selection reflects the increasing complexity of navigating biologic options in a clinical environment.